Related Experiment Videos
[Interferon-alpha and PUVA therapy for mycosis fungoides]
M Marschalkó1, J Kovács, B Somlai
1Altalános Orvostudomanyi Kar, Bór- és Nemikórtani Klinika, Semmelweis Egyetem, Budapest.
Abstract:
14 patients suffering from early stage mycosis fungoides were treated with interferon alpha 2-a and PUVA/1 patient in stage I a, 3 patients in stage I b, 4 patients in stage II a and 6 patients in stage II b/during 3-21 months time course. Interferon alpha 2-a was administered 3 times a week, in escalating dose from 3 MU to 9 MU, determining the individual maximal tolerated dose. All of the patients responded well to the treatment. Partial remission was observed after 4-13 weeks of treatment. Total remission developed in 8 cases, after 8 weeks- 9 months of the treatment. Side effects occurred frequently: weight loss, pain, fever, fatigue, leucopenia, thrombopenia, liver enzyme elevation. Because of the side effects the dose of the interferon was reduced individually, the dose reduction did not cause relapse.
Insights
This study shows that interferon alpha 2-a combined with PUVA therapy effectively treats early-stage mycosis fungoides, achieving remission in all patients. Side effects were manageable with dose adjustments, preventing relapse.
Area of Science:
- Dermatology
- Oncology
- Immunology
Context:
- Mycosis fungoides is a type of cutaneous T-cell lymphoma.
- Early-stage disease often requires combination therapies for optimal outcomes.
- Interferon alfa-2a and PUVA are established treatment modalities.
Purpose:
- To evaluate the efficacy and safety of interferon alfa-2a combined with PUVA therapy in patients with early-stage mycosis fungoides.
- To determine the optimal dosing and management of side effects associated with this combination therapy.
Summary:
- Fourteen patients with early-stage mycosis fungoides (stages Ia to IIb) received interferon alfa-2a (3-9 MU thrice weekly) and PUVA therapy for 3-21 months.
- All patients demonstrated positive responses, with partial remission in 4-13 weeks and complete remission in 8 cases (8 weeks to 9 months).
- Common side effects included weight loss, pain, fever, fatigue, leucopenia, thrombopenia, and elevated liver enzymes, which were managed by dose reduction without inducing relapse.
Impact:
- This combination therapy shows significant efficacy in treating early-stage mycosis fungoides.
- Interferon alfa-2a dose modification is a viable strategy to manage treatment-related side effects.
- Further research can explore long-term outcomes and refine treatment protocols.